title: Mobilization of peripheral stem cells with intensive chemotherapy (ICE regimen) and G-CSF in chronic myeloid leukemia.
abstract: Seventeen patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) were treated with the ICE regimen plus G-CSF with the aim of mobilizing and collecting Ph-negative peripheral stem cells (PSC) in the setting of an autotransplant program. Fifteen patients had CML in first chronic phase (CP), and two in accelerated phase (AP). Three patients had been previously treated with interferon alpha 2a (IFN). Twelve patients underwent leukaphereses and a mean of 4.7 x 10(8)/kg mononuclear cells were obtained. Four CP patients did not show a significant mobilization peak of CD34+ cells and leukapheresis was not performed; finally, one patient died before apheresis could be performed. Six of the 12 who underwent leukaphereses obtained more than 1.0 x 10(6)/kg CD34+ cells. Eight of the 12 mobilized patients (67%) obtained a major cytogenetic response, including two complete and six partial; in the remaining four patients minimal or absent cytogenetic responses were observed. A higher rate of Ph purging was obtained in patients mobilized early or showing residual Ph-negative cells before mobilization, even if they were in AP. Infectious complications were frequent with a 38% rate of bacteremia recorded and one case of pulmonary aspergillosis resulting in a toxicity similar to that occurring in acute myeloid leukemia-induction chemotherapy. The ICE regimen can promote 'in vivo' purging of the Ph+ cells in 67% of CML mobilized patients (8/12). Failure of mobilization occurs in 65% of patients (11/17), mainly because of poor CD34+ cell yield.
authors.affiliation: Servei d'Hematologia Clinica, Institut Català d'Oncologia, Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Boqué
authors.forename: J
authors.initials: J
authors.lastname: Petit
authors.forename: J
authors.initials: J
authors.lastname: Sarrá
authors.forename: J A
authors.initials: JA
authors.lastname: Cancelas
authors.forename: J
authors.initials: J
authors.lastname: Muñoz
authors.forename: J I
authors.initials: JI
authors.lastname: Español
authors.forename: E
authors.initials: E
authors.lastname: de la Banda
authors.forename: A
authors.initials: A
authors.lastname: Aventin
authors.forename: J
authors.initials: J
authors.lastname: Berlanga
authors.forename: C
authors.initials: C
authors.lastname: Ferrá
authors.forename: B
authors.initials: B
authors.lastname: Amill
authors.forename: C
authors.initials: C
authors.lastname: Torrico
authors.forename: C
authors.initials: C
authors.lastname: Azqueta
authors.forename: M
authors.initials: M
authors.lastname: Llucià
authors.forename: J
authors.initials: J
authors.lastname: García
authors.forename: A
authors.initials: A
authors.lastname: Grañena
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002469:Cell Separation; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide